Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42)

Abstract

Supplemental Digital Content is available in the text

Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis

“…These findings are similar to those from previous reports in Japan. 6,19,20 TZDs and glinides were the least frequently prescribed OADs, and treatment persistence was shortest for α-GIs and SUs. We believe treatment persistence is a result of several Considering patient baseline characteristics, the increasing severity of RI was consistent with ageing and higher rates of comorbidities.…”

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes

“…Although metformin is the first‐line drug in Western countries, the use of DPP‐4 inhibitors has been increasing in Japan: according to an analysis of the Japan Medical Data Centre Claims Database (Japan Medical Data Centre Co. Ltd, Tokyo, Japan), ~70% of Japanese patients with T2DM use DPP‐4 inhibitors, and ~60% of patients receiving DPP‐4 inhibitors are drug‐naïve . In some cases, however, it is difficult to control blood glucose using a DPP‐4 inhibitor alone . In such cases, combining a DPP‐4 inhibitor with an SGLT2 inhibitor is a possible option, but this combination has yet to be fully evaluated in Japanese patients.…”

“…2 In some cases, however, it is difficult to control blood glucose using a DPP-4 inhibitor alone. [11][12][13] In such cases, combining a DPP-4 inhibitor with an SGLT2 inhibitor is a possible option, but this combination has yet to be fully evaluated in Japanese patients. Owing to the differences in T2DM pathology and treatment algorithms between Japanese and Western populations, the results of studies examining combination therapy with a DPP-4 inhibitor and an SGLT2 inhibitor in Western patients may not be generalizable to Japanese patients; therefore, it is important to examine the efficacy and safety of this combination in Japanese patients.…”

Association between dipeptidyl peptidase‐4 inhibitors and urinary tract infection in elderly patients: A retrospective cohort study

“…All patients were at least 75 years of age and were covered by the Latter‐Stage Elderly Health Insurance. DPP‐4 inhibitors and sulfonylureas (SUs) are 2 important second‐line antidiabetic agents, and are the most prescribed in Japan . We identified 34 394 study patients who were prescribed DPP‐4 inhibitors or SUs between the fiscal years 2011 and 2016.…”

“…DPP-4 inhibitors and sulfonylureas (SUs) are 2 important second-line antidiabetic agents, 10 and are the most prescribed in Japan. 11 We identified 34 394 study patients who were prescribed DPP-4 inhibitors or SUs between the fiscal years 2011 and 2016. Among them, 9282 patients who were prescribed DPP-4 inhibitors in combination with SUs on same date were excluded.…”